Kraig Biocraft Laboratories, Inc. (KBLB)
| Previous close | 0.0395 |
| Open | 0.0390 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0375 - 0.0400 |
| 52-week range | 0.0300 - 0.1000 |
| Volume | |
| Avg. volume | 875,844 |
| Market cap | 39.462M |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0090 |
| Earnings date | 14 Mar 2023 - 20 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the la
- GlobeNewswire
Kraig Biocraft Laboratories Completes Closeout of $8 Million Financing, Extinguishing All Convertible Debentures with Yorkville Advisors
ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Adviso
- GlobeNewswire
Kraig Biocraft Laboratories poised to Close Out Yorkville Convertible Debenture with Strongest Financial Position in Corporate History
ANN ARBOR, Mich., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company's hi
